SGLT2 inhibitors: an Evidence-Based Update on cardiovascular Implications
Expert Opin Investig Drugs. 2023 Sep 23. doi: 10.1080/13543784.2023.2263354. Online ahead of print.ABSTRACTINTRODUCTION: Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent randomized clinical trials have demonstrated important cardioprotective effects of gliflozins, independent of the presence of diabetes. Herein, we summarize the recent therapeutic progress in the cardiovascular field obtained with SGLT2 inhibitors.AREA COVERED: This review critically examines the rationale and results of recent clinical studies examining the effects of SGLT2 inhibitors on cardiovascular outcomes, along with a brief overview of the main ongoing trials that have been designed in order to answer the many unanswered questions in the field of gliflozins and cardiovascular disease.EXPERT OPINION: The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects of SGLT2 inhibitors.PMID:37740906 | DOI:10.1080/13543784.2023.2263354
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Authors: Imma Forzano Scott Wilson Angela Lombardi Stanislovas S Jankauskas Urna Kansakar Pasquale Mone Fahimeh Varzideh Varzideh Gaetano Santulli Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Drugs & Pharmacology | Endocrinology | Heart | SGLT2 Inhibitors | Sodium | Study